ETFs Holding RPRX »    RPRX Historical Stock Prices »
RPRX News Video: Wed, Dec 7, 2016, 12:41 PM — Wednesday Sector Laggards: Drugs, Biotechnology Stocks

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Repros Therapeutics is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. Co. is developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Co. is also developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound, for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Enclomiphene treats the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Self directed investors in Repros Therapeutics Inc will be interested in keeping up with all Repros Therapeutics Inc news they can find, both RPRX news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on RPRX. At RediNews, we simplify this task by presenting both RPRX news releases originating from Repros Therapeutics Inc itself, and RPRX news from a variety of media outlets. Visitors can browse this news online and through our RPRX RSS news feed.


RPRX News — Articles, Videos, & Press Releases

RPRX is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

ZMH News
THC News
STE News

RediNews invites you to integrate our free RSS news feeds. While web portal content experience like building out an investor relations web site is a major plus when working with our RSS feeds, you don't need stock quote feed experience to begin working with something as simple as RSS — which stands for Really Simple Syndication. Although such experience could lead to some great custom market content ideas like a custom stock ticker with related news included, you don't need to be at the level of head of IR content for an IR services firm to work with our feeds. And unlike investor relations data feeds that typically carry steep licensing feeds, our RediNews RSS feeds are provided to you free of charge. To give our feeds a try, look for the RSS icon for any news page (which will look like this): .

RPRX News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.